AIDS Update, Laboratory Centre for Disease Control, Ottawa, March 19, 1987.
2.
AIDS Update, Laboratory Centre for Disease Control, Ottawa, July 27, 1987.
3.
BoykoW.J., SchechterM.T., CraibK.J.P.The Vancouver Lymphadenopathy-AIDS Study, Part V: Antecedent behavioural, clinical and laboratory parameters in AIDS patients versus HTLV-III positive controls. Can Med Assoc J1986; 135: 881–7.
4.
BoykoW.J., SchechterM.T., JeffriesE., DouglasB., MaynardM., and O'ShaughnessyM.The Vancouver Lymphadenopathy-AIDS Study, Part III: Relation of HTLV-III seropositivity, immune status and lymphadenopathy. Can Med Assoc J1985; 133: 28–32.
5.
GoldstoneI.L., BoldingB., and BeaufoyA.Caring for the AIDS patient. Registered Nurses’ Association of British Columbia News1985; 17: 6, 11–12.
6.
JeffriesE., WilloughbyB., BoykoW.J.The Vancouver Lymphadenopathy-AIDS Study, Part II: Seroepidemiology of HTLV-III antibody. Can Med Assoc J1985; 132: 1373–7.
7.
McLeodW.A., SmithT., and WilloughbyB.Hospice care of AIDS patients. J of Palliative Care1986; 2(1): 33–34.
8.
RekartM.Verbal communication, May 13, 1987.
9.
SchechterM.T., BoykoW.J., DouglasB.The Vancouver Lymphadenopathy-AIDS Study, Part VI: HIV seroconversion in a cohort of homosexual men. Can Med Assoc J1986; 135: 1355–60.
10.
SchechterM.T., BoykoW.J., JeffriesE., WilloughbyB., NitzR., and ConstanceP.The Vancouver Lymphadenopathy-AIDS Study, Part I: Persistent generalized lymphadenopa-thy. Can Med Assoc J1985; 132: 1273–9.
11.
SchechterM.T., BoykoW.J., JeffriesE.The Vancouver Lymphadenopathy-AIDS Study, Part IV: Effects of exposure factors, co-factors and HTLV-III seropositivity on number of helper T cells. Can Med Assoc J1985; 133: 286–92.
12.
McLeanH.E.Dr, Consultant, Communicable Diseases, Vancouver Health Department. Verbal communication, July 22, 1987.